Bio-Techne stock

TECH · NASDAQ · USD

Compare Bio-Techne
$72.63Change from previous close: −0.22%Absolute change: −$0.16

Close · November 17, 2026

Price history

+24.17% over the period

1 year: from $58.61 (November 17, 2025) to $72.78 (November 17, 2026), +24.17%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$72.78
October 30, 2026$72.66
September 30, 2026$72.47
August 31, 2026$72.31
July 31, 2026$72.09
June 30, 2026$70.65
May 29, 2026$51.68
April 30, 2026$55.32
March 31, 2026$52.26
February 27, 2026$59.00
January 30, 2026$64.09
December 31, 2025$58.81
November 28, 2025$64.51
November 17, 2025$58.61

At a glance

  • The company

    Develops and manufactures life science reagents, instruments and services for research, diagnostics and bioprocessing markets globally

  • Latest results

    Quarter to September 30, 2026 · EPS $0.44 (estimate $0.45)

TickerLandia's take on Bio-Techne

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$43.20
52-wk high$72.88

−0.34% from the 52-week high

Analysts · 13 analysts

Average target$70.50−2.93% vs. price

Buy 0 · Hold 12 · Sell 1 · Hold

TickerLandia Fingerprint: Bio-Techne

Compared with similar companies: very high earnings stability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Bio-Techne is priced as in the past and in line with similar companies

On the latest fiscal year's earnings (2026), Bio-Techne's P/E today is 62.7, in line with the median of its last 6 fiscal years (64.6; between 46.4 and 129.4 from 2021 to 2026). Bio-Techne's P/E (trailing 12 months): 66.8, in line with the median of a group of 7 similar companies (66.8).

P/E compared with its history

Compared with 7 similar companies

Bio-Techne's metrics compared with similar companies
MetricBio-TechnePosition in the groupBand
P/E (trailing 12 months)66.8Middle
Forward P/E31.5High
Operating margin21.7%Middle
ROE8.3%Middle
Debt/equity0.13Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Bio-Techne. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$299.71M

Latest quarter · Q3 2026

Net income

$28.29M

Latest quarter · Q3 2026

Quarterly net margin

9.4%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$11.43B
P/E
66.8
EPS
$1.09
Volume
3.5M
Daily trading
€204.3M
Dividend yield
0.44%
Last ex-dividend on November 13, 2026

How Bio-Techne is changing

All results
  • Revenue grew 5.5% a year on average over the last 5 years

  • Operating margin fell from 26.3% to 20.7%

  • Profits turn into cash: free cash flow equal to 179% of net income

Returns

Bio-Techne returns with dividends

$1,000 invested in Bio-Techne 5 years ago, on November 17, 2021, would be worth $603 today with dividends reinvested: −39.68% in total, −9.62% per year. On price alone it would be $589 (−41.06%).

PeriodBio-TechneS&P 500$1,000 becomes
1 month+0.39%−3.17%$1,004
6 months+67.74%+0.11%$1,677
Year to date+23.75%+8.34%$1,237
1 year+24.83%+11.15%$1,248
3 years+21.05%+64.30%$1,210
5 years−39.68%+58.18%$603
10 years+192.23%+239.10%$2,922

Over the last 6 months it has done better than 95% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Bio-Techne: technical analysis

Bio-Techne is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 46.1% below its highest close since January 2, 1990 ($134.72, September 24, 2021).

Trend
Upward
RSI (14 sessions)
48
Between 30 and 70
vs 200-session average
+14.45%

Active signals

  • The price is moving in an unusually narrow range compared with the last year.

    since August 25, 2026

Support and resistance

Price areas where Bio-Techne has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$72.63
  3. Support$72.34−0.40%15 touches, last on November 9, 2026
  4. Support$70.20−3.34%2 touches, last on July 8, 2026
  5. Support$58.73−19.14%2 touches, last on February 27, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.60
Volatility (60 sessions, annualised)
1.9%
Largest fall in the last year
−39.34%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Bio-Techne: seasonality

Average monthly price change over 37 years

−1.6%Jan+2.1%Feb+1.1%Mar+2.6%Apr+5.0%May+4.2%Jun+2.0%Jul+1.1%Aug+0.5%Sep+2.6%Oct+2.7%Nov+1.9%Dec

Over the last 37 years, the strongest month for Bio-Techne has been May: +5.02% on average, positive in 21 years out of 37. The weakest has been January: −1.56% on average, positive in 17 years out of 36. November, the current month, has been positive in 23 years out of 36 (+2.67% on average).

Show chart data
MonthAverageMedianPositive years
January−1.56%−0.01%17 of 36
February+2.15%+2.13%20 of 37
March+1.06%+0.39%19 of 37
April+2.57%+3.27%22 of 37
May+5.02%+2.39%21 of 37
June+4.18%+2.29%21 of 37
July+2.00%+1.65%22 of 37
August+1.15%+0.31%19 of 37
September+0.50%0.00%18 of 37
October+2.55%+1.60%23 of 37
November+2.67%+2.51%23 of 36
December+1.85%+1.26%22 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Bio-Techne and its competitors

Based in Minneapolis, Minnesota, Bio-Techne has existed since its incorporation in 1976. Its portfolio centers on biological reagents such as cytokines, growth factors and antibodies, supplied to research laboratories, clinical diagnostics makers and developers of cell and gene therapies. It also offers diagnostic controls, calibrators and assays, tissue-based spatial analysis kits, and instruments and control products for hematology and blood chemistry. Known as Techne Corporation until November 2014, it serves customers across many countries.

Headquarters
Minneapolis, United States
Employees
3,000
Founded
1976
Chief executive
Kim Kelderman
Bio-Techne and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Bio-TechneTECH$11.43B21.7%66.8+67.74%
Summit TherapeuticsSMMT$11.32B0.0%—−36.75%
BioMarin PharmaceuticalBMRN$11.09B16.3%146.8+12.93%
Madrigal PharmaceuticalsMDGL$9.93B-10.7%—−19.42%
Corcept TherapeuticsCORT$9.36B0.8%190.2+24.30%
Halozyme TherapeuticsHALO$14.67B56.8%38.3+42.98%

Same industry or related industries, similar size. Compare Bio-Techne with its competitors · Full profile